Multiple Myeloma Clinical Trial
— AZABACHEOfficial title:
Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group
Verified date | April 2020 |
Source | PETHEMA Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Assessment of the antitumour effect of zoledronic acid in patients with multiple myeloma and
asymptomatic biochemical relapse
It´s proposed to investigate the use of Zoledronic acid as single therapy in patients with
Multiple Myeloma in biochemical relapse. The following must be noted:
- Patients with no formal indication for chemotherapy treatment will be included, as
patients with symptomatic myeloma who after responding show biochemical relapse are
generally not treated. This allows for generating both a group of patients untreated, on
no additional treatment and a treatment group on zoledronic acid.
- As these are relapsing symptomatic patients, their number is far higher than patients
with quiescent Multiple Myeloma. This allows for expecting a good enrolment.
- There are few reliable data on symptom progression after biochemical relapse, though it
is one of the new objectives occurring in almost all clinical trials on myeloma. In the
VISTA study, it has been estimated that the median time to the new treatment is 5 months
(combining progression-free time and time to the next treatment). This time is much
shorter than the median quiescent myeloma progression-free survival, so a very long
follow-up time will not be necessary in this patient group.
- The administration of this drug to these patients can help prevent skeleton-related
complications in the future, the study of which will be a secondary objective of this
study.
Status | Completed |
Enrollment | 103 |
Est. completion date | June 5, 2013 |
Est. primary completion date | May 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male or female patients aged =18 years. - Signed informed consent before performing any study procedure that is not the part of the regular medical care of the patients. - Diagnosis of MM, with biochemical relapse after initial response with no symptoms resulting from the disease (CRAB), defined as a re-positivation of a previous immunofixation (two samples) or increase above 25% of serum or urine protein M. - In the investigator's opinion, ability to meet all clinical trial requirements Exclusion Criteria: - Treatment with bisphosphonates (oral route and/or endovenous route) within 3 months prior to inclusion. - Treatment with denosumab within three months prior to inclusion. - Criteria of symptomatic disease or organic damage related to disease, defined as: - Impaired renal function: serum creatinine >2 mg/dl or 173 mmol/l. Calcium increase: serum calcium =12 mg/dl within 28 days prior to inclusion. - Anaemia: haemoglobin < 10 g/dl or 2 g/dl below normal ranges. - Bone injury: new osteolytic lesions (from diagnosis) seen within 3 months prior to inclusion, current pathological fractures or increase of osteopenia (from diagnosis) in bone radiology series. - Others: amyloidosis with current organic damage, recurrent bacterial infections (more than 2 events in 12 months), symptomatic hyperviscosity, presence of plasmacytomas. - Patients with current and active dental disorders (dental, jaw infection, bone exposed in the mouth, jaw osteonecrosis). - Patients developing jaw osteonecrosis or other serious adverse events due to treatment with any bisphosphonate . - Significant liver disease: - Bilirubin > 3 g/dl. - ALT > 2.5 x the upper limit of normal - AST > 2.5 x the upper limit of normal - Patients who are currently in another clinical trial or receiving any investigational agent. - Pregnancy or nursing. - Parathyroid gland diseases. - Previous malignancy with a high risk of death or bone disease: breast cancer, prostate cancer or lung cancer, even if on complete response. - Active presence of neoplasms other than Multiple Myeloma |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitari Germans Trias I Pujol | Badalona | |
Spain | Hospital de la Santa Creu i Sant Pau | Barcelona | |
Spain | Hospital del Mar | Barcelona | |
Spain | Hospital Vall d'Hebrón | Barcelona | |
Spain | Hospital Clínico San Carlos | Madrid | |
Spain | Hospital Universitario Ramón y Cajal | Madrid | |
Spain | Hospital Jose María Morales Meseguer | Murcia | |
Spain | Hospital Central de Asturias | Oviedo | |
Spain | Hospital Son Llàtzer | Palma de Mallorca | |
Spain | Hospital Universitario Son Dureta | Palma de Mallorca | |
Spain | Hospital Universitario de Salamanca | Salamanca | |
Spain | Hospital Universitario de Canarias | Tenerife | |
Spain | Hospital Clínico Universitario de Valencia | Valencia | |
Spain | Hospital Universitario Dr. Peset. | Valencia | |
Spain | Hospital Universitario La Fe | Valencia | |
Spain | Hospital Clínico Lozano Blesa | Zaragoza |
Lead Sponsor | Collaborator |
---|---|
PETHEMA Foundation | Dynamic Solutions, Novartis |
Spain,
R. García-Sanz, A. Oriol, J. de la Rubia, L. Palomera, P. Ribas, MT. Hernández, MJ. Moreno, J. Bargay, A. Ramírez, AI. Teruel, MJ. Blanchard, M. Gironella, M. Granell, E. Abellá, MA Sampol, R. Martínez, JF San Miguel EVALUTION OF BENEFITS AND POTENTIAL AN
R. García-Sanz, A. Oriol, J. de la Rubia, L. Palomera, P. Ribas, MT. Hernández, MJ. Moreno, J. Bargay, A. Ramírez, AI. Teruel, MJ. Blanchard, M. Gironella, M. Granell, E. Abellá, MA Sampol, R. Martínez, JF San Miguel EVALUTION OF BENEFITS AND POTENTIAL AN
R. García-Sanz, A. Oriol, J. de la Rubia, L. Palomera, P. Ribas, MT. Hernández, MJ. Moreno, J. Bargay, A. Ramírez, AI. Teruel, MJ. Blanchard, M. Gironella, M. Granell, E. Abellá, MA Sampol, R. Martínez, JF San Miguel EVALUTION OF BENEFITS AND POTENTIAL AN
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to next need treatment | Time to the next treatment, considered as the time from the randomization date to the start of the next chemotherapy treatment for Multiple Mieloma or death for any cause | 6 months | |
Secondary | Time to symptom relapse | Time to symptom relapse, considered as the time from randomization to symptom relapse | 1 year | |
Secondary | disease progression | To describe the differences between patients treated with ZOL or not in terms of type of disease progression (bone and extra-bone). | 2 years | |
Secondary | prognostic factors | To describe the prognostic factors in patients with MM and asymptomatic biochemical relapse | 2 years | |
Secondary | antitumour effect of ZOL | To assess the antitumour effect of ZOL on other clinically significant parameters in MM, including tumour response to ZOL | 1 year | |
Secondary | Overall survival | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |